Ocumension Therapeutics Company Description

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China.

It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.

The company was founded in 2017 and is based in Suzhou, the People's Republic of China.

Ocumension Therapeutics

Country	Cayman Islands
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	505
CEO	Ye Liu

Contact Details

Address: No. 1858 Yinzhongnan Road Suzhou China
Website	ocumension.com

Stock Details

Ticker Symbol	1477
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG674111011
SIC Code	2834

Key Executives

Name	Position
Ye Liu	Chief Executive Officer and Executive Director
Dr. Zhaopeng Hu	Chief Development Officer and Executive Director
Tim Ruan	Chief Financial Officer and Joint Company Secretary
Qinglei Zuo	Chief Commercial Officer
Dr. Yang Shen	Chief Medical Officer
Hongying Liu	Chief Internal Audit Officer
Tingchan Chen	Joint Company Secretary